ACRV Acrivon Therapeutics, Inc.

Nasdaq acrivon.com


$ 2.15 $ 0.00 (0 %)    

Wednesday, 05-Nov-2025 08:18:17 EST
QQQ $ 618.49 $ 0.00 (0 %)
DIA $ 470.92 $ 0.00 (0 %)
SPY $ 674.77 $ 0.00 (0 %)
TLT $ 89.83 $ 0.00 (0 %)
GLD $ 365.78 $ 0.00 (0 %)
$ 2.15
$ 2.26
$ 2.14 x 29
$ 2.16 x 110
-- - --
$ 1.05 - $ 8.74
1,212,542
na
44.9M
$ 1.39
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-28-2023 12-31-2022 10-K
12 12-15-2022 09-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 acrivon-therapeutics-to-deliver-three-presentations-at-the-aacr-nci-eortc-highlighting-advances-from-its-proprietary-generative-phosphoproteomics-ap3-platform-for-developing-precision-medicines

AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal ...

 oppenheimer-maintains-outperform-on-acrivon-therapeutics-lowers-price-target-to-8

Oppenheimer analyst Matthew Biegler maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and lowers the price targ...

 acrivon-therapeutics-q2-eps-055-beats-058-estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of ...

 jones-trading-downgrades-acrivon-therapeutics-to-hold

Jones Trading analyst Soumit Roy downgrades Acrivon Therapeutics (NASDAQ:ACRV) from Buy to Hold.

 acrivon-therapeutics-q1-eps-051-beats-066-estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of ...

 acrivon-therapeutics-announces-it-will-present-data-from-ap3-generative-phosphoproteomic-analyses-of-acr-2316-regulated-cdk1--cdk2--and-plk1-induced-pathways-at--a-american-association-for-cancer-research-annual-meeting-april-25-30-2025-in-chicago-illinois

Presentation to highlight how AP3 Generative Phosphoproteomic analyses uncover how ACR-2316 induces mitotic and replicative tum...

 hc-wainwright--co-reiterates-buy-on-acrivon-therapeutics-maintains-19-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $19 pric...

 acrivon-therapeutics-q4-2024-gaap-eps-060-beats-066-estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of ...

 cantor-fitzgerald-reiterates-overweight-on-acrivon-therapeuticsto-overweight

Cantor Fitzgerald analyst Li Watsek reiterates Acrivon Therapeutics (NASDAQ:ACRV) from Overweight to Overweight.

 citizens-capital-markets-reiterates-market-outperform-on-acrivon-therapeutics-maintains-17-price-target

Citizens Capital Markets analyst Silvan Tuerkcan reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Market Outperform and ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION